Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022 Jul 1;17(4):192-198. doi: 10.1097/COH.0000000000000735. PMID: 35762373; PMCID: PMC9467455.
Purpose of Review: The main reason for failure of oral pre-exposure prophylaxis (PrEP) regimens for HIV is poor adherence. Intramuscular cabotegravir was recently approved for PrEP, and a number of other long-acting antiretroviral formulations and products are currently in clinical development. This includes subcutaneous and intravenous injections, implants, and microarray (microneedle) patches, as well as extended duration oral drugs. The success and future uptake of these products will depend on a variety of factors.
Recent Findings: Long-acting delivery of antiretroviral agents for PrEP confers significant advantages over short-acting oral delivery. This is exemplified by the superior efficacy of intramuscular cabotegravir given every eight weeks as compared to daily oral co-formulated tenofovir disoproxil fumarate and emtricitabine. There is also evidence for PrEP efficacy for a broadly-neutralizing monoclonal antibody given intravenously every eight weeks. One of the leading candidates for long-acting PrEP, islatravir, was being studied as a monthly oral drug or a non-erodable subcutaneous implant inserted for up to 12 months. However, clinical studies of this agent were put on hold in late 2021 because of unanticipated lymphopenia.
Summary: Long-acting antiretroviral products have substantial promise for PrEP, and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of health care delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.